Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. / Yde, Christina Westmose; Gyrd-Hansen, Mads; Lykkesfeldt, Anne E; Issinger, Olaf-Georg; Stenvang, Jan.

In: Molecular Cancer Therapeutics, Vol. 6, No. 6, 06.2007, p. 1869-1876.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Yde, CW, Gyrd-Hansen, M, Lykkesfeldt, AE, Issinger, O-G & Stenvang, J 2007, 'Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death', Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1869-1876. https://doi.org/10.1158/1535-7163.MCT-07-0072

APA

Yde, C. W., Gyrd-Hansen, M., Lykkesfeldt, A. E., Issinger, O-G., & Stenvang, J. (2007). Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Molecular Cancer Therapeutics, 6(6), 1869-1876. https://doi.org/10.1158/1535-7163.MCT-07-0072

Vancouver

Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger O-G, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Molecular Cancer Therapeutics. 2007 Jun;6(6):1869-1876. https://doi.org/10.1158/1535-7163.MCT-07-0072

Author

Yde, Christina Westmose ; Gyrd-Hansen, Mads ; Lykkesfeldt, Anne E ; Issinger, Olaf-Georg ; Stenvang, Jan. / Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 6. pp. 1869-1876.

Bibtex

@article{5fa962d020ec11ddbc23000ea68e967b,
title = "Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death",
abstract = "Antiestrogens are currently used for treating breast cancer patients who have estrogen receptor-positive tumors. However, patients with advanced disease will eventually develop resistance to the drugs. Therefore, compounds effective on antiestrogen-resistant tumors will be of great importance for future breast cancer treatment. In this study, we have investigated the effect of the chemotherapeutic compound cisplatin using a panel of antiestrogen-resistant breast cancer cell lines established from the human breast cancer cell line MCF-7. We show that the antiestrogen-resistant cells are significantly more sensitive to cisplatin-induced cell death than antiestrogen-sensitive MCF-7 cells and we show that cisplatin induces cell death by activating both the caspase and lysosomal death pathways. The antiestrogen-resistant cell lines express lower levels of antiapoptotic Bcl-2 protein compared with parental MCF-7 cells. Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment.",
keywords = "Antineoplastic Agents, Blotting, Western, Breast Neoplasms, Caspases, Cell Death, Cell Line, Tumor, Cisplatin, Estrogen Receptor Modulators, Humans, Peptide Hydrolases",
author = "Yde, {Christina Westmose} and Mads Gyrd-Hansen and Lykkesfeldt, {Anne E} and Olaf-Georg Issinger and Jan Stenvang",
year = "2007",
month = jun,
doi = "10.1158/1535-7163.MCT-07-0072",
language = "English",
volume = "6",
pages = "1869--1876",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research (A A C R)",
number = "6",

}

RIS

TY - JOUR

T1 - Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

AU - Yde, Christina Westmose

AU - Gyrd-Hansen, Mads

AU - Lykkesfeldt, Anne E

AU - Issinger, Olaf-Georg

AU - Stenvang, Jan

PY - 2007/6

Y1 - 2007/6

N2 - Antiestrogens are currently used for treating breast cancer patients who have estrogen receptor-positive tumors. However, patients with advanced disease will eventually develop resistance to the drugs. Therefore, compounds effective on antiestrogen-resistant tumors will be of great importance for future breast cancer treatment. In this study, we have investigated the effect of the chemotherapeutic compound cisplatin using a panel of antiestrogen-resistant breast cancer cell lines established from the human breast cancer cell line MCF-7. We show that the antiestrogen-resistant cells are significantly more sensitive to cisplatin-induced cell death than antiestrogen-sensitive MCF-7 cells and we show that cisplatin induces cell death by activating both the caspase and lysosomal death pathways. The antiestrogen-resistant cell lines express lower levels of antiapoptotic Bcl-2 protein compared with parental MCF-7 cells. Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment.

AB - Antiestrogens are currently used for treating breast cancer patients who have estrogen receptor-positive tumors. However, patients with advanced disease will eventually develop resistance to the drugs. Therefore, compounds effective on antiestrogen-resistant tumors will be of great importance for future breast cancer treatment. In this study, we have investigated the effect of the chemotherapeutic compound cisplatin using a panel of antiestrogen-resistant breast cancer cell lines established from the human breast cancer cell line MCF-7. We show that the antiestrogen-resistant cells are significantly more sensitive to cisplatin-induced cell death than antiestrogen-sensitive MCF-7 cells and we show that cisplatin induces cell death by activating both the caspase and lysosomal death pathways. The antiestrogen-resistant cell lines express lower levels of antiapoptotic Bcl-2 protein compared with parental MCF-7 cells. Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment.

KW - Antineoplastic Agents

KW - Blotting, Western

KW - Breast Neoplasms

KW - Caspases

KW - Cell Death

KW - Cell Line, Tumor

KW - Cisplatin

KW - Estrogen Receptor Modulators

KW - Humans

KW - Peptide Hydrolases

U2 - 10.1158/1535-7163.MCT-07-0072

DO - 10.1158/1535-7163.MCT-07-0072

M3 - Journal article

C2 - 17575115

VL - 6

SP - 1869

EP - 1876

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -

ID: 4043846